# An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

> **NCT02831764** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 722 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** Dolutegravir (DTG)
- **DRUG:** Lamivudine (3TC)
- **DRUG:** Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

## Key facts

- **NCT ID:** NCT02831764
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-18
- **Primary completion:** 2018-04-04
- **Final completion:** 2022-06-29
- **Target enrollment:** 722 (ACTUAL)
- **Last updated:** 2023-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831764, "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02831764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*